Izalontamab brengitecan

{
  "id": "MLC-T-ONC-014610",
  "term": "Izalontamab brengitecan",
  "field": "Oncology and biomedicine",
  "definition": "A dual-targeted antibody-drug conjugate (ADC) consisting of a bispecific antibody directed against both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3) conjugated, via a cathepsin-B cleavable linker, to the camptothecin derivative and topoisomerase 1 inhibitor Ed-04, with potential antineoplastic activity. Upon administration of izalontamab brengitecan, the bispecific antibody moiety simultaneously targets and binds to EGFR and HER3 expressed on cancer cells. Upon binding and internalization, Ed-04 is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing EGFR and/or HER3. EGFR and HER3, both upregulated and/or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation. Simultaneously targeting both EGFR and HER3 may enhance the anti-tumor activity of izalontamab brengitecan.",
  "synonyms": [
    "ADC BL-B01D1",
    "anti-EGFR/anti-HER3 ADC BL-B01D1",
    "anti-EGFR/HER3 ADC BL-B01D1",
    "dual antibody ADC BL-B01D1",
    "dual target ADC BL-B01D1"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/izalontamab-brengitecan/"
}